Patents Assigned to IPSEN PHARMA
-
Patent number: 11753633Abstract: Embodied herein are engineered fusion proteins that bind and target nociceptor neurons, compositions comprising these engineered fusion proteins, and methods for treatment of pain using these engineered fusion proteins or compositions containing the engineered fusion proteins. The engineered fusion proteins contain domains derived from protein toxins such as the anthrax toxin, clostridial botulinum family of toxins, disulphide-containing toxins, and AB component type toxins.Type: GrantFiled: August 26, 2016Date of Patent: September 12, 2023Assignees: President and Fellows of Harvard College, Massachusetts Institute of Technology, IPSEN PHARMA S.A.S.Inventors: R. John Collier, Isaac Chiu, Bradley L. Pentelute, Keith Alan Foster, Shilpa Palan, Sai Man Liu
-
Publication number: 20200360483Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.Type: ApplicationFiled: February 3, 2020Publication date: November 19, 2020Applicant: Ipsen Pharma S.A.S.Inventors: Zheng Xin DONG, John E. Taylor, Rakesh Datta, Michael DeWitt Culler
-
Publication number: 20200347110Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.Type: ApplicationFiled: December 20, 2019Publication date: November 5, 2020Applicant: Ipsen Pharma S.A.S.Inventors: Rakesh Datta, Zheng Xin Dong
-
Patent number: 10792433Abstract: The present invention concerns a syringe assembly comprising a hollow tubular syringe body, having a proximal end and a distal end, a plunger rod, axially movable in the syringe body between an initial position and a final position. The assembly also includes a support transversally stiff for supporting the plunger rod, the support having a distal end and a proximal end respectively transversally fixed to the syringe body and to the plunger rod, the proximal end of the support being movable with respect to the syringe body.Type: GrantFiled: July 1, 2016Date of Patent: October 6, 2020Assignee: IPSEN PHARMAInventors: Steven Mark Guy Rolfe, Andrew Lewis
-
Patent number: 10787696Abstract: A system for the identification of proteases and protease inhibitors is provided. The system has at least two components. The first component is a reporter construct with at least one binding site, a transcriptional promoter, an inducible promoter region, and at least one reporter gene, all functionally connected for expression of the reporter gene(s) in functional coordination with a transcriptional activation agent. The second component is a transcriptional activation agent comprising a nucleic acid binding domain, at least one protease substrate domain, and at least one transcriptional activation domain for an inducible promoter. The system allows detection and evaluation of agents affecting protease activity directed to the protease substrate domain. The system also allows for the detection of the presence of proteases in environmental samples.Type: GrantFiled: September 13, 2013Date of Patent: September 29, 2020Assignee: IPSEN PHARMA S.A.S.Inventors: George A. Oyler, Yung-Nien Chang, Yien Che Tsai
-
Publication number: 20200095281Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.Type: ApplicationFiled: December 4, 2019Publication date: March 26, 2020Applicant: Ipsen Pharma S.A.S.Inventors: Zheng Xin DONG, Jacques-Pierre MOREAU
-
Patent number: 10543249Abstract: A pharmaceutical composition for a sustained release of peptide therapeutics, in particular for a sustained release compatible with therapeutic treatments of at least two months. In an embodiment, the composition comprises lanreotide as an active agent, a hydrosoluble co-solvent, and water with the pH of the composition being from 4.0 to 7.5.Type: GrantFiled: July 8, 2014Date of Patent: January 28, 2020Assignee: IPSEN PHARMA S.A.S.Inventors: Ruth Bielsa Guivernau, Roland Cherif-Cheikh, Julie Fournes, Daniel Martinez Lorente, Anne Petit, Joël Richard
-
Publication number: 20200017548Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2??(I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.Type: ApplicationFiled: September 25, 2019Publication date: January 16, 2020Applicant: Ipsen Pharma S.A.S.Inventor: Zheng Xin DONG
-
Publication number: 20190248861Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.Type: ApplicationFiled: October 24, 2018Publication date: August 15, 2019Applicant: Ipsen Pharma S.A.S.Inventors: Rakesh Datta, Zheng Xin Dong
-
Publication number: 20190167754Abstract: Process for the preparation of an injectable pharmaceutical composition for the sustained release of somatostatin analogues. Composition prepared according to such a process.Type: ApplicationFiled: December 26, 2018Publication date: June 6, 2019Applicant: IPSEN PHARMA S.A.S.Inventors: Martin MONTES, Thomas Ciaran Loughman, Chantal Roume, Roland Cherif-Cheikh
-
Publication number: 20190111105Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.Type: ApplicationFiled: December 19, 2018Publication date: April 18, 2019Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
-
Publication number: 20190062374Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.Type: ApplicationFiled: November 12, 2018Publication date: February 28, 2019Applicant: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
-
Patent number: 10206968Abstract: A process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogs and compositions prepared according to the process. The process may comprise lyophilizing a mixture of lanreotide acetate and acetic acid to form a lyophilizate and hydrating the lyophilizate, wherein the lyophilization is performed only once.Type: GrantFiled: April 27, 2016Date of Patent: February 19, 2019Assignee: IPSEN PHARMA S.A.S.Inventors: Martin Montes, Thomas Ciaran Loughman, Chantal Roume, Roland Cherif-Cheikh
-
Publication number: 20180303899Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.Type: ApplicationFiled: November 2, 2017Publication date: October 25, 2018Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
-
Publication number: 20180305406Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.Type: ApplicationFiled: July 9, 2018Publication date: October 25, 2018Applicant: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
-
Publication number: 20180169343Abstract: The present invention concerns a syringe assembly comprising a hollow tubular syringe body, having a proximal end and a distal end, a plunger rod, axially movable in the syringe body between an initial position and a final position. The assembly also includes a support transversally stiff for supporting the plunger rod, the support having a distal end and a proximal end respectively transversally fixed to the syringe body and to the plunger rod, the proximal end of the support being movable with respect to the syringe body.Type: ApplicationFiled: July 1, 2016Publication date: June 21, 2018Applicant: IPSEN PHARMAInventors: Steven Mark Guy ROLFE, Andrew LEWIS
-
Patent number: 9975880Abstract: Imidazolidine-2,4-dione derivatives of formula (I): These compounds have anti-proliferative activity and are useful for treating pathological states and diseases linked to an abnormal cell proliferation, such as cancer.Type: GrantFiled: December 31, 2013Date of Patent: May 22, 2018Assignee: IPSEN PHARMA S.A.S.Inventors: Serge Auvin, Christophe Lanco, Oliver Dutruel, Qi Chao, Kaichun Gu
-
Publication number: 20180118784Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.Type: ApplicationFiled: August 29, 2017Publication date: May 3, 2018Applicant: Ipsen Pharma S.A.S.Inventors: Zheng Xin DONG, Daniel B. DEOLIVEIRA, Jeanne Mary COMSTOCK
-
Publication number: 20180105557Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.Type: ApplicationFiled: December 4, 2017Publication date: April 19, 2018Applicant: Ipsen Pharma S.A.S.Inventors: Zheng Xin DONG, Jacques-Pierre MOREAU
-
Patent number: RE49444Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: GrantFiled: December 24, 2020Date of Patent: March 7, 2023Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle, Zhengxin Dong